BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

532 related articles for article (PubMed ID: 36475850)

  • 1.
    Zhang T; Du J; Dong L; Wang F; Zhao L; Jia J; Wang C; Cheng M; Yu X; Huang H
    Microbiol Spectr; 2023 Feb; 11(1):e0323822. PubMed ID: 36475850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omadacycline, Eravacycline, and Tigecycline Express Anti-Mycobacterium abscessus Activity
    Li A; He S; Li J; Zhang Z; Li B; Chu H
    Microbiol Spectr; 2023 Jun; 11(3):e0071823. PubMed ID: 37140428
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Brown-Elliott BA; Wallace RJ
    Antimicrob Agents Chemother; 2022 Sep; 66(9):e0068922. PubMed ID: 35943269
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Brown-Elliott BA; Wallace RJ
    Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33288634
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Kaushik A; Ammerman NC; Martins O; Parrish NM; Nuermberger EL
    Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30962331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria.
    Wallace RJ; Brown-Elliott BA; Crist CJ; Mann L; Wilson RW
    Antimicrob Agents Chemother; 2002 Oct; 46(10):3164-7. PubMed ID: 12234839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic activities of tigecycline with clarithromycin or amikacin against rapidly growing mycobacteria in Taiwan.
    Huang CW; Chen JH; Hu ST; Huang WC; Lee YC; Huang CC; Shen GH
    Int J Antimicrob Agents; 2013 Mar; 41(3):218-23. PubMed ID: 23312605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimicrobial susceptibility testing of rapidly growing mycobacteria isolated in Japan.
    Hatakeyama S; Ohama Y; Okazaki M; Nukui Y; Moriya K
    BMC Infect Dis; 2017 Mar; 17(1):197. PubMed ID: 28270102
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Shoen C; Benaroch D; Sklaney M; Cynamon M
    Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30858221
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Fujiwara K; Aono A; Asami T; Morimoto K; Kamada K; Morishige Y; Igarashi Y; Chikamatsu K; Murase Y; Yamada H; Takaki A; Mitarai S
    Antimicrob Agents Chemother; 2023 Jun; 67(6):e0157922. PubMed ID: 37154742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro susceptibility testing of tetracycline-class antibiotics against slowly growing non-tuberculous mycobacteria.
    Li A; Tan Z; He S; Chu H
    Clin Exp Pharmacol Physiol; 2023 Jul; 50(7):604-609. PubMed ID: 37086075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potency of Omadacycline against Mycobacteroides abscessus Clinical Isolates
    Nicklas DA; Maggioncalda EC; Story-Roller E; Eichelman B; Tabor C; Serio AW; Keepers TR; Chitra S; Lamichhane G
    Antimicrob Agents Chemother; 2022 Jan; 66(1):e0170421. PubMed ID: 34662184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omadacycline as a promising new agent for the treatment of infections with Mycobacterium abscessus.
    Bax HI; de Vogel CP; Mouton JW; de Steenwinkel JEM
    J Antimicrob Chemother; 2019 Oct; 74(10):2930-2933. PubMed ID: 31236595
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Cheng A; Tsai YT; Chang SY; Sun HY; Wu UI; Sheng WH; Chen YC; Chang SC
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative
    Mirza HC; Güçlü AÜ; İnce Ceviz G; Başustaoğlu A
    J Med Microbiol; 2022 Oct; 71(10):. PubMed ID: 36301611
    [No Abstract]   [Full Text] [Related]  

  • 16. Omadacycline for management of Mycobacterium abscessus infections: a review of its effectiveness, place in therapy, and considerations for use.
    Rizzo AR; Moniri NH
    BMC Infect Dis; 2022 Nov; 22(1):874. PubMed ID: 36419143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibiotic resistance in
    Jayasingam SD; Zin T; Ngeow YF
    Int J Mycobacteriol; 2017; 6(4):387-390. PubMed ID: 29171453
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Luo J; Yu X; Jiang G; Fu Y; Huo F; Ma Y; Wang F; Shang Y; Liang Q; Xue Y; Huang H
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29760127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Evaluation of Antimicrobial Susceptibilities of Rapidly Growing Mycobacteria].
    Özkarataş MH; Arslan N; Esen N; Özkütük AA
    Mikrobiyol Bul; 2023 Apr; 57(2):220-237. PubMed ID: 37067207
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Brown-Elliott BA; Wallace RJ
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30509936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.